Short Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Expands By 35.9%

Aquestive Therapeutics, Inc. (NASDAQ:AQST) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 10,370,000 shares, a growth of 35.9% from the June 30th total of 7,630,000 shares. Based on an average daily volume of 1,700,000 shares, the short-interest ratio is currently 6.1 days.

Aquestive Therapeutics Trading Up 10.7 %

Shares of AQST opened at $3.82 on Monday. The business’s 50 day moving average is $2.83 and its 200 day moving average is $3.31. The company has a market capitalization of $347.77 million, a PE ratio of -9.10 and a beta of 2.80. Aquestive Therapeutics has a 12-month low of $1.25 and a 12-month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, May 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The company had revenue of $12.05 million during the quarter, compared to the consensus estimate of $12.22 million. During the same quarter in the previous year, the business earned $0.11 earnings per share. Equities research analysts predict that Aquestive Therapeutics will post -0.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. SVB Leerink assumed coverage on Aquestive Therapeutics in a research report on Friday, May 10th. They issued an “outperform” rating and a $8.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Wednesday, June 26th. Piper Sandler initiated coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They issued an “overweight” rating and a $10.00 price objective on the stock. Leerink Partnrs raised Aquestive Therapeutics to a “strong-buy” rating in a research note on Friday, May 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Friday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $7.83.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $54,000. Lazard Asset Management LLC increased its stake in Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares during the last quarter. Jump Financial LLC bought a new stake in Aquestive Therapeutics in the 4th quarter worth approximately $60,000. PFG Investments LLC bought a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $204,000. Finally, Virtu Financial LLC increased its stake in Aquestive Therapeutics by 219.7% in the 1st quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock worth $438,000 after acquiring an additional 70,666 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.